JC03 Rec'd PCT/PTO 2 1 SEP 200

PTO/SB/21 (09-04)

8 /	U.S.	Patent and Trader	nark Office;	U.S. DEPARTMENT OF COMMERCE
Andrew the Paperwork Reduction Act of 1995.	Application Number	10/539,049	ion unless i	displays a valid CMB control number.
TRANSMITTAL	Filing Date	16 December 2	003	
FORM	First Named Inventor	ABBOTT, Frank Slade		
	Art Unit			
(to be used for all correspondence after initial fil	Examiner Name			
Total Number of Pages in This Submission	8 Attorney Docket Number	U008 0645		
	ENCLOSURES (Check al	i that apply)		
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on Ci	Address	Appea of App Appea (Appea (Appea) Propri Status Other below	Allowance Communication to TC al Communication to Board beals and Interferences al Communication to TC al Notice, Brief, Reply Brief) letary Information s Letter Enclosure(s) (please Identify): n of receipt postcard.
Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks TOO ARRIVE A TOO		CENT	
Firm Name	URE OF APPLICANT, ATTO	KNET, UK A	GENI	
Oyen Wiggs Green & Mutal Signature Printed name Grace S. Law	a LLP			
Date 20 September 2005 V		Reg. No. 56,	135	
I hereby certify that this correspondence is bei sufficient postage as first class mail in an enve the date shown below: Signature		O or deposited	with the Un	
Typed or printed name	<u></u>		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SEP 21 2005 BOOLINAP

PTO/SB/08A (07-05)

Approved for use through 07/31/2006, OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of 7

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/539,049				
Filing Date	16 December 2003				
First Named Inventor	ABBOTT, Frank Slade				
Art Unit					
Examiner Name					
Attorney Docket Number	U008 0645				

	U. S. PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
		^{US-} 2002/0156320 A1	10-24-2002	Nau					
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							

	FORE	IGN PATENT DOCU	JMENTS		
Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
	Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T
	WO 94/06743 A	03-31-1994	Bojic et al.		
					L
 		-			L
					┡
 -				 	╄
I				1	

		_
Examiner	Date	
Signature	Considered	
Oignature	Constitution	1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC

Substitu	te for form 1449/PTO			re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
		Application Number	10/539,049				
		Filing Date	16 December 2003				
		First Named Inventor	ABBOTT, Frank Slade				
	<i>(11)</i>			Art Unit			
	(Use as many she	ets as n	ecess <i>ary)</i>	Examiner Name			
Sheet	2	of	7	Attorney Docket Number	U008 0645		

	r	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Dreifuss, F. E., Santili, N., Langer, D. H., Sweeny, K. P., Moline, K. A., Menander, K. B., Valproic acid hepatic fatalities: a retrospective*, Neurology, 37, 379-385 (1987).	
		Kesterson, J.W. et al., The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies, Hep., 4, 1143-1152 (1984).	
		Kingsley, E.; Gray, P.; Tolman, K. G.; Tweedale, R. The toxicity of metabolites of sodium valproate in cultured hepatocytes, J. Clin. Pharmacol., 23, 178-185 (1983).	
		Kassahun, K., Farrell, K., Abbott, F.S., Identification and characterization of the glutathione and N-acetylcysteine*, Drug Metab. Dispos., 19, 525-535 (1991).	
		Genton, P. et al., Valproic Acid, Adverse Effects, in Antiepileptic Drugs, 5th edition, Rene H Levy et al. eds., Lippincott Williams and Wilkins, NY, 2002, p 837-851.	
		Abbott, F. S., Anari, M. R., "Chemistry and biotransformation"in Valproate, Milestones in Drug Therapy, W. Loscher, ed., Birhauser Verlag, Basel, 1999, p. 47-75.	
		Radatz , M.; Nau, H. "Toxicity" in Valproate, Milestones in Drug Therapy, W. Loscher, ed., Birhauser Verlag, Basel, 1999, p. 91-128.	
		Tabatabaei, A. R. et al., A rapid in vitro assay for evaluation of metabolism-dependent cytotoxicity of antiepileptic drugs*, Fundam Appl Toxicol. 37, 181-189 (1997).	
		Winn, L. M., Wells, P. G., Maternal administration of superoxide dismutase and catalase in phenytoin teratogenicity, Free Radic, Biol. Med., 26, 266-274 (1999).	
		Tang, W. et al., Fluorinated analogues as mechanistic probes in valproic acid (VPA) hepatotoxicity: Hepatic microvesicular*, Chem. Res. Toxicol., 8, 671-682 (1995).	

Examiner	-	Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

U008 0645

McGer the Paperwork Reduction Act of 1995, no persons at	U.S. Pater re required to respond to a collection	Approved for use inrough 0/31/2006. On the and Trademark Office; U.S. DEPARTMENT OF on of information unless it contains a valid OMB co Complete if Known	COMMERCE
Substitute 10 Total 1445/FTO	Application Number	10/539,049	
INFORMATION DISCLOSURE	Filing Date	16 December 2003	
STATEMENT BY APPLICANT	First Named Inventor	ABBOTT, Frank Slade	
	Art Unit		
(Use as many sheets as necessary)	Examiner Name		

Attorney Docket Number

Sheet 3 of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	ART ARTIST	Tang, W. et al., Characterization of thiol conjugated metabolites of 2-propyl-4-pentenoic acid (4-ene-VPA), a toxic metabolite of valp*J. Mass Spectrom., 31, 926-936 (1996).	
		Tang, W., Palaty, J., Abbott,F.S., Time course of •-fluorinated valproic acid in mouse brain and serum and its effect on sym.*,J. Phar. Exp. Therap, 282, 1163-1172 (1997).	
·		Palaty, J., Abbott, F. S. Structure-activity relationships of unsaturated analogues of valproic acid, J. Med. Chem., 38, 3398-3406 (1995).	
		Düsing, R. H., Single dose tolerance and pharmacokinetics of 2-n-propyl-(2E)-pentenoate •2E-valproate) in healthy male volunteers, Pharm. Week., 14, 152-158 (1992).	
		Elmazar, M. M. A., Hauck, RS., Nau, H., Anticonvulsant and neurotoxic activities of twelve analogues of valproic acid, J. Pharm. Sci., 82, 1255-1258 (1993).	
		Hauck, R. S., Nau, H., The enantiomers of the valproic acid analog 2-n-propyl-4-pentynoic acid (4-yn-VPA): asymmetyric synthesis and highly stereo*, Pharm. Res., 9, 855 (1992).	
		Parisi, M. F., Gattuso, G., Notti, A., and Raymo, F. M., J. Org. Chem., 1995, 60, 5174-5179.	
		Litchfield, J. T., Wilcoxon, F. J. Phar. Exp. Ther., 1949, 96, 99-113.	
		Tong, V., Chang, T. K. H., Chen, J., Abbott, F. S., The effect of valproic acid on hepatic and plasma levels of 15-F2t-Isopro*, Free Radic. Biol. Med., 34, 1435-1446 (2003).	
		Sokol, R.J. et al., Role of oxidant stress in the permeability transition induced in rat hepatic mitochondria by hydrophobic bile acids, Pediatric Res., 49, 519-531 (2001).	

Examiner	 Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031

u	er the Paperwork Rec	luction A	ct of 1995, no persons ar	o.s. Patent re_required to respond to a collection	of information unless it contains a valid OMB con	COMMERCE ntrol number.
So Strute for form 1449/PTO		Complete if Known				
3				Application Number	10/539,049	
INFORMATION DISCLOSURE		Filing Date	16 December 2003			
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	ABBOTT, Frank Slade	
				Art Unit		
	(Use as many she	ets as n	ecessary)	Examiner Name		
Sheet	4	of	7	Attorney Docket Number	U008 0645	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Qu, B. et al., Mechanism of clofibrate hepatotoxicity: Mitochondrial damage and oxidative stress in hepatocytes, Free Radic. Biol. Med., 31, 659-669 (2001).	
		Tang, W., Abbott, F. S., A comparative investigation of 2-propyl-4-pentenoic acid (4-ene-VPA) and its •-fluorinated analogue in: phase*, Drug Metab. Disp., 25, 219-227 (1997).	
		Tsunoda, T., Suzuki, M., Noyori, R. A., A facile procedure for acetalization under aprotic conditions, Tetrahedron Lett., 21, 1357-1358 (1980).	
		Ohshima T. Et al., Asymmetric Heck Reaction – Carbanion Capture Process. Catalytic Asymmetric Total Synthesis of (-)-•9(12)-Cap*, J. Am. Chem. Soc., 118, 7108-7116 (1996).	
		Aubert, C. et al., Alkylation du trifluoacetylacetate d'ethyle methode generale d'acces aux trifluoromethylcetones. 2ieme partie: Alkyla*, J. Fluor. Chem., 44, 377-394 (1989).	
		Montes de Lopez-Cepero, I., Santiago, A., Larson, G. L., A Synthesis of 2,2-ethylenedioxy-5-ketones, Synth. Commun., 16, 705-711 (1986).	
		Kurihara, M., Hakamata, W., Convenient preparation of cyclic acetals, using diols, TMS-source, and a catalytic amount of TMSOTF, J. Org. Chem., 68, 3413-34515 (2003).	
		Middleton, W. J., New fluorinating reagents. Dialkylaminosulfur fluorides, J. Org. Chem., 40, 574-578 (1975).	
		Middleton, W. J., Bingham, E. M., •,•-Difluoroarylacetic acids: Preparation from (diethylamino)sulfur trifluoride and •-oxoarylacetates, J. Org. Chem., 45, 2883-2887 (1980).	
		Lal, G. S. et al., Bis(2-methoxyethyl)aminosulfur trifluoride: A new broad-spectrum deoxofluorinating agent with enhanced thermal stab.*, J. Org. Chem. 64, 7048-7054 (1999).	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO		·····	e required to respond to a collection	Complete if Known			
Jubantu	10 10 10 111 1443/1 10			Application Number	10/539,049			
INF	ORMATION	I DIS	CLOSURE	Filing Date	16 December 2003			
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	ABBOTT, Frank Slade			
	<i>at</i>			Art Unit				
	(Use as many she	ets as n	ecessary)	Examiner Name				
Sheet	5	of	7	Attorney Docket Number	U008 0645			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Lal, G. S. et al., Bis(2-methoxyethyl)amino sulfur trifluoride: A new broad-spectrum deoxofluorinating agent with enhanced thermal stability, Chem. Commun., 215-216 (1998).	
		Singh, R. P., Majumder, U., Shreeve, J. M., Nucleophilic Di- and Tetrafluorination of dicarbonyl compounds, J. Org. Chem., 66, 6263-6267 (2001).	
		Tsuji, J., Synthetic applications of the palladium-catalyzed oxidation of olefins to ketones, Synthesis, 369-384 (1983).	
		Tsuji, J., Mizatani, K., Shimzu, I., Yamamoto, K., Synthesis of 2,15-hexadecanedione, a precursor of muscone, from butadiene, Chem. Lett., 773-774 (1976).	
		Tsuji, J. et al., Convenient general synthetic method for 1,4- and 1,5-diketones by palladium catalyzed oxidation of*, Tetrahedron Lett., 34, 2975-2976 (1976).	
		Brun, E. M., Gil. S., Mestres, R., Parra, M., Regioselective alkylation of lithium dienediolates of •,•-unsaturated carboxylic acids, Synthesis, 1160-1165 (2000).	
		Brun, E. M., Gil. S., Mestres, R., Parra, M., New conditions for the generation of dianions of carboxylic acids, Tethedron Lett., 39, 5443-5446 (1998).	
		Yoshida, Y. et al., Practical and efficient methods for sulfonylation of alcohols using Ts(Ms)Cl/Et3N and*Tetrahedron, 55, 2183-2192 (1999).	
		Wakabayashi, T., Mori, K., Kobayashi, S., Total synthesis and structural elucidation of Khafrefungin, J. Am. Chem. Soc., 123, 1372-1375 (2001).	
		Lee, R. D., Kassahun, K., Abbott, F. S., Stereoselective synthesis of the diunsaturated metabolites of valproic acid, J. Pharm. Sci., 78, 667-671 (1989).	

Examiner		Date	
Signature	•	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SEP 21 2005 WHE

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substit	ute for form 1449/PTO				Complete if Known	
	~			Application Number	10/539,049	
INF	ORMATION	DIS	SCLOSURE	Filing Date	16 December 2003	
ST	ATEMENT E	BY A	PPLICANT	First Named Inventor	ABBOTT, Frank Slade	
	41			Art Unit		
	(Use as many she	ets as i	necessary)	Examiner Name		
Sheet	6	of	7	Attorney Docket Number	U008 0645	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Maryanoff, B.E.; Reitz, A.B. Chem. Rev. 1989, 89, 863-927 and references therein.	
		(a) DiBiase, S.A.; Lipisko, B.A.; Haag, A.; Wolak, R.A.; Gokel, G.W. J. Org. Chem. 1979, 44, 4640-4649;	
		(b) Wu, K.M.; Midland, M.M.; Okamura, W.H. J. Org. Chem. 1990, 55, 4355, 4381-4392;	
		(c) Clive, D.L.J.; Farina, V.; Beaulieu, P.L. J. Org. Chem. 1982, 47, 2572-2582;	
		(d) Ono, N.; Miyake, H.; Tanikaga, R.; Kaji, A. J. Org. Chem. 1982, 47, 5017-5019.	
		Takacs, J.M.; Jaber, M.R.; Clement, F.; Walters, C. J. Org. Chem. 1998, 63, 6757- 6760.	
_		Bonadies, F.; Cardilli, A.; Lattanzi, A.; Orelli, L.R.; Scettri, A. Tetrahedron Letters 1994, 35, 3383-3386.	
		Bennani, Y.L.; Boehm, M.F. J. Org. Chem. 1995, 60, 1195-1200.	
		Motoyoshiya, J. Trends in Organic Chemistry, 1998, 7, 63-73 and references therein.	
		Pihko, P.M.; Salo, T.M. Tetrahedron Letters, 2003, 44, 4361-4364 and references therein.	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE r the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known stitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

7 of

Sheet

Complete in the control of the contr				
Application Number	10/539,049			
Filing Date	16 December 2003			
First Named Inventor	ABBOTT, Frank Slade			
Art Unit				
Examiner Name				
Attorney Docket Number	11000 0645			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		INTERNATIONAL SEARCHING AUTHORITY, International Search Report for PCT/CA03/01960, 2 August 2004, References cited below	
		DREIDING, Andre S. et al., ".alpha and .gamma Additions in the Reformatskii reaction with methyl gamma-bromocrotonate", Jr. of American Chem. Soc., 75:3717-23 (1953).	
		TAKEUCHI, Yoshio et al., "The first general and efficient method for synthesis of teritary alkyl fluorides", Jr of Organic chem, 58(13), 3483-5 (1993).	
		MYERS, Andrew G. et al., "Synthesis of tertiary alkyl fluoride centers by asymmetric C-C(F) bond formation" Tetrahedron Letters, 38(40), 7037-7040 (1997).	
		ZHU, Gui-Dong et al., "Intramolecular Diels-Alder reaction of 8-trifluoromethyl-1,3,8-nonatrienes: an access to angular*" Bull. Des Soc. Chim. Belges, 103(5-6), 263-71 (1994).	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. 1 Applicant's unique citation designation number (optional). 2 Applicant is to piace a check mark here it English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.